Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBU NASDAQ:GNTA NASDAQ:NGEN NASDAQ:OKUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBUCaribou Biosciences$1.77+5.4%$1.97$1.22▼$3.54$166.62M2.332.39 million shs2.80 million shsGNTAGenenta Science$1.80-0.6%$1.17$0.55▼$10.00$42.70M0.93.94 million shs260,633 shsNGENNervGen Pharma$1.96+4.8%$2.66$1.70▼$6.30$158.04MN/A463,405 shs805,719 shsOKUROnKure Therapeutics$4.50$4.25$1.91▼$5.38$181.78M0.28555,593 shs414,099 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBUCaribou Biosciences0.00%+2.75%-28.81%-2.33%+33.33%GNTAGenenta Science0.00%+7.74%+75.73%+187.30%-41.61%NGENNervGen Pharma0.00%-15.00%-9.66%+186,999,900.00%+186,999,900.00%OKUROnKure Therapeutics0.00%+0.45%+7.14%+18.73%+87.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBUCaribou Biosciences$1.77+5.4%$1.97$1.22▼$3.54$166.62M2.332.39 million shs2.80 million shsGNTAGenenta Science$1.80-0.6%$1.17$0.55▼$10.00$42.70M0.93.94 million shs260,633 shsNGENNervGen Pharma$1.96+4.8%$2.66$1.70▼$6.30$158.04MN/A463,405 shs805,719 shsOKUROnKure Therapeutics$4.50$4.25$1.91▼$5.38$181.78M0.28555,593 shs414,099 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBUCaribou Biosciences0.00%+2.75%-28.81%-2.33%+33.33%GNTAGenenta Science0.00%+7.74%+75.73%+187.30%-41.61%NGENNervGen Pharma0.00%-15.00%-9.66%+186,999,900.00%+186,999,900.00%OKUROnKure Therapeutics0.00%+0.45%+7.14%+18.73%+87.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBUCaribou Biosciences 2.75Moderate Buy$8.67389.64% UpsideGNTAGenenta Science 1.00SellN/AN/ANGENNervGen Pharma 2.80Moderate Buy$18.00818.37% UpsideOKUROnKure Therapeutics 2.00Hold$27.00500.00% UpsideCurrent Analyst Ratings BreakdownLatest GNTA, OKUR, CRBU, and NGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026GNTAGenenta Science Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/11/2026NGENNervGen Pharma TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/29/2026OKUROnKure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/11/2026OKUROnKure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026CRBUCaribou Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $11.005/7/2026OKUROnKure Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/29/2026NGENNervGen Pharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/28/2026NGENNervGen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/27/2026NGENNervGen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.004/24/2026NGENNervGen Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (D-)4/24/2026OKUROnKure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBUCaribou Biosciences$11.16M15.73N/AN/A$1.31 per share1.35GNTAGenenta ScienceN/AN/AN/AN/A$1.29 per shareN/ANGENNervGen PharmaN/AN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/A$4.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBUCaribou Biosciences-$148.12M-$1.42N/AN/AN/A-1,189.14%-84.17%-60.51%8/11/2026 (Estimated)GNTAGenenta Science-$7.39MN/AN/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)NGENNervGen PharmaN/A-$0.09N/AN/AN/AN/AN/AN/AN/AOKUROnKure Therapeutics-$59.52M-$4.33N/AN/AN/AN/A-61.02%-55.99%8/11/2026 (Estimated)Latest GNTA, OKUR, CRBU, and NGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026NGENNervGen Pharma-$0.07$999.00+$999.07$999.00N/AN/A5/7/2026Q1 2026CRBUCaribou Biosciences-$0.33-$0.26+$0.07-$0.26$2.21 million$2.40 million5/5/2026Q1 2026OKUROnKure Therapeutics-$0.7425-$1.11-$0.3675-$1.11$0.17 millionN/A3/31/2026Q4 2025GNTAGenenta Science-$0.3641-$0.0750+$0.2891-$0.0750N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRBUCaribou BiosciencesN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/ANGENNervGen PharmaN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBUCaribou BiosciencesN/A6.226.22GNTAGenenta Science0.3514.1614.16NGENNervGen PharmaN/AN/AN/AOKUROnKure TherapeuticsN/A13.7813.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBUCaribou Biosciences77.51%GNTAGenenta Science15.13%NGENNervGen PharmaN/AOKUROnKure Therapeutics90.98%Insider OwnershipCompanyInsider OwnershipCRBUCaribou Biosciences8.54%GNTAGenenta Science28.99%NGENNervGen Pharma5.80%OKUROnKure Therapeutics17.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBUCaribou Biosciences10099.18 million90.71 millionOptionableGNTAGenenta Science723.59 million16.75 millionNot OptionableNGENNervGen PharmaN/A80.63 millionN/AN/AOKUROnKure TherapeuticsN/A40.40 million33.16 millionN/AGNTA, OKUR, CRBU, and NGEN HeadlinesRecent News About These CompaniesFinancial Analysis: Aspire Biopharma (NASDAQ:ASBP) & OnKure Therapeutics (NASDAQ:OKUR)June 19, 2026 | americanbankingnews.comOnKure Therapeutics, Inc. Class AJune 9, 2026 | edition.cnn.comOnKure Shareholders Approve Amended 2024 Equity Incentive PlanJune 4, 2026 | tipranks.comOnkure Therapeutics (OKUR) Stock Forecast & Price TargetMay 22, 2026 | investing.comOnKure Therapeutics (OKUR) Receives a Buy from OppenheimerMay 8, 2026 | theglobeandmail.comOnKure Therapeutics war chest nears $200M following spring stock saleMay 6, 2026 | bizwest.comBOnKure Therapeutics Reports First Quarter 2026 Financial ResultsMay 5, 2026 | globenewswire.comOnKure Therapeutics (OKUR) price target decreased by 15.13% to 20.60April 28, 2026 | msn.comOnKure Therapeutics (OKUR) Gets a Buy from JonesTradingApril 26, 2026 | theglobeandmail.comOnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and ...March 27, 2026 | finance.yahoo.comOnKure to sell $150M in stock to fund drug developmentMarch 27, 2026 | bizwest.comBOnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular AnomaliesMarch 27, 2026 | globenewswire.comOnKure reports nearly $60M cash on hand as drug trials continueMarch 19, 2026 | bizwest.comBOnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 12, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), OnKure Therapeutics (OKUR) and Praxis Precision Medicines (PRAX)January 24, 2026 | theglobeandmail.comOnKure Therapeutics (OKUR) Price Target Decreased by 10.00% to 27.54November 18, 2025 | msn.comOnKure Therapeutics Announces Sales Agreement with LeerinkNovember 13, 2025 | theglobeandmail.comOnKure Therapeutics reports Q3 EPS ($1.09), consensus ($1.20)November 7, 2025 | msn.comOnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business UpdateNovember 6, 2025 | globenewswire.comOnKure Therapeutics to Participate in Upcoming Investor ConferencesNovember 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNTA, OKUR, CRBU, and NGEN Company DescriptionsCaribou Biosciences NASDAQ:CRBU$1.77 +0.09 (+5.36%) Closing price 04:00 PM EasternExtended Trading$1.79 +0.02 (+1.13%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Genenta Science NASDAQ:GNTA$1.80 -0.01 (-0.55%) Closing price 04:00 PM EasternExtended Trading$1.80 -0.01 (-0.28%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.NervGen Pharma NASDAQ:NGEN$1.96 +0.09 (+4.81%) Closing price 04:00 PM EasternExtended Trading$2.00 +0.04 (+2.30%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.OnKure Therapeutics NASDAQ:OKUR$4.50 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$4.50 0.00 (-0.11%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
